Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans

Kidney International

Volumn 51, Issue 4, 1997, Pages 1188-1195

  Dooley, Mary Anne ^a   Hogan, Susan ^a   Jennette, Charles ^a   Falk, Ronald ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Div of Nephrology and Hypertension   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; ETHNIC AND RACIAL GROUPS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL;

EID: 0030902221     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1997.162     Document Type: Article

References (53)

1. AUSTIN HA, KLIPPEL JH, BALOW JE, LE RICHE NGH, STEINBERG AD, PLOTZ PH, DECKER J: Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614-619, 1986
2. VALERI A, RADHAKRISHNAN J, ESTES D, D'AGATI V, KOPELMAN R, PERNIS A, FLIS R, PIRANI C, APPEL GB: Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: A prospective five-year study. Clin Nephrol 42:71-78, 1994
3. LEHMAN TJ, SHERRY DD, WAGNER-WEINER L, MCCURDY DK, EMERY HM, MAGILAVY DB: Intermittent intravenous cyclophosphmaide therapy for lupus nephritis. J Pediatr 114:1055-1060, 1989
4. BOUMPAS DT, AUSTIN HA, VAUGHN EM, KLIPPEL JH, STEINBERG AD, YARBORO CH, BALOW JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-745, 1992
5. SIEGAL M, HOLLEY HL, LEE SL: Epidemiologic studies on systemic lupus erythematosus: Comparative data for New York City and Jefferson County, Alabama, 1956-1965. Arthritis Rheum 13:802-811, 1970
6. FESSEL WJ: Systemic lupus erythematosus in the community: Incidence, prevalence, outcome and first symptoms: The high prevalence in black women. Arch Intern Med 134:1027-1035, 1974
7. HOCHBERG MC: The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970-1977. Arthritis Rheum 28:80-86, 1985
8. SIEGAL M, GWON N, LEE SL, RIVERO I, WONG W: Survivorship in systemic lupus erythematosus: Relationships to race and pregnancy. Arthritis Rheum 12:117-125, 1969
9. GINZLER EM, DIAMOND HS, WEINER M: A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 25:601-611, 1982
10. STUDENSKI S, ALLEN NB, CALDWELL DS, RICE JR, POLISSON RP: Survival in systemic lupus erythematosus: A multivariate analysis of demographic factors. Arthritis Rheum 30:1326-1331, 1987
11. REVEILLE JD, BARTOLUCCI A, ALARCON GS: Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, Black race, and thrombocytoppenia, as well as causes of death. Arthritis Rheum 33:37-48, 1990
12. WALSH SJ, ALGERT C, GREGORIO DI, REISINE ST, ROTHFIELD NF: Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol 22:1663-1668, 1995
13. BALDWIN DS, GLUCK MC, LOWENSTEIN J, GALLO GR: Lupus nephritis. Clinical course as related to morphologic forms and their transitions. Am J Med 62:12, 1977
14. APPEL GB, COHEN DJ, PIRANI CL, MELTZER JI, ESTES D: Long-term follow up of patients with lupus nephritis. A study based on the classification of the world health organization. Am J Med 83:877-885, 1987
15. DONADIO JV, HART GM, BERGSTAL H, HOLLEY KE: Prognostic determinants in lupus nephritis: A long-term clinicopathologic study. Lupus 4:109-115, 1995
16. TAN EM, COHEN AS, FRIES J: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277, 1982
17. CATHCART ES, IDELSON BA, SCHEINBERG MA, COUSER WG: Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis. Lancet I:163-166, 1976
18. DOSA S, CAIRNS SA, LAWLER W, MALLICK NP, SLOTKI IN: The treatment of lupus nephritis by methylprednisolone pulse therapy. Postgrad Med J 54:628-632, 1978
19. KIMBERLY RP, LOCHSHIN MD, SHERMAN RL: High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am J Med 70:817-823, 1981
20. ISENBERG DA, MORROW WJ, SNAITH ML: Methylprednisolone pulse therapy in the treatment of systemic lupus erythematosus. Ann Rheum Dis 41:347-351, 1982
21. LEIBLING MR, MCLAUGHLIN K, BOONSUE S, KASDIN J, BARNETT EV: Monthly pulses of methylprednisolone in SLE nephritis. J Rheumatol 9:543-548, 1982
22. BALLOU SP, KHAN MA, KUSHNER I: Intravenous pulse methylprednisolone followed by alternate day corticosteroid therapy in lupus erythematosus: a prospective evaluation. J Rheumatol 12:944-948, 1985
23. PONTICELLI C, ZUCCHELLI P, MORONI G, CAGNOLI L, BANEI G, FASCUALI S: Long-term prognosis of diffuse lupus nephritis. Clin Nephrol 28:263-271, 1987
24. CHURG J, SOBIN LH: Renal Disease: Classification and Atlas of Glomerular Disease. Tokyo, Igaku-Shoin, 1982, pp 127-149
25. AUSTIN HA, MUENZ LR, JOYCE KM, ANTONOVYCH TA, KULLICK ME, KLIPPEL JH, DECKER JL, BALOW JE: Prognostic factors in lupus nephritis: Contribution of renal histological data. Am J Med 75:382-390, 1983
26. KAPLAN EL, MEIER P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. SO Y: Procedure for Cox s Proportional Hazards Regression Analysis. SAS Institute, Inc., Application Division, SAS Users Group International Conference, 1991
28. BOUMPAS DT, AUSTIN HA, FESSLER BJ, BALOW JE, KLIPPEL JH, LOCKSHIN MD: Systemic lupus erythematosus: Emerging concepts. Part I. Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 122:940-950, 1995
29. POLLACK VE, PIRANI CL, SCHWARTZ FD: The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 63:537, 1964
30. ZWEIMAN B, KORNBLUM J, CORNOG J HILDRETH EA: The prognosis of lupus nephritis. Role of clinical-pathologic correlations. Ann Int Med 69:441, 1968
31. CHEATUM DE, HURD ER, STRUNK SW, ZIFF M: Renal histology and clinical course of systemic lupus erythematosus. A prospective study. Arthritis Rheum 16:670, 1973
32. BALDWIN DS, GLUCK MC, LOWENSTEIN J, GALLO GR: Lupus nephritis. Clinical course as related to morphologic forms and their transitions. Am J Med 62:12, 1977
33. KIMBERLY RP, LOCKSHIN MD, SHERMAN RL, BEARY JF MOURADIAN J, CHEIGH JS: "End-stage" lupus nephritis: Clinical course to and outcome on dialysis. Experience with 39 patients. Medicine 60:277-287, 1981
34. BALLOU SP, KHAN MA, KUSHNER I: Clinical features of sytemic lupus erythematosus. Differences related to race and age of onset. Arthritis Rheum 25:55-60, 1982
35. HOCHBERG MC, BOYD RE, AHEARN JM: Sytemic lupus erythematosus: A review of clinico-laboralory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine 64:285-295, 1985
36. PETRI M, PEREZ-GUTTHAHN S, LONGENECKER C, HOCHBERG M: Morbidity of systemic lupus erythematosus: Role of race and socio-economic status. Am J Med 91:345-353, 1991
37. WARD MM, PYUN E, STUDENSKI S: Long-term survival in systemic lupus erythematosus. Arthritis Rheum 274-283, 1995
38. WARD MM, STUDENSKI S: Clinical manifestations of systemic lupus erythematosus: Identification of racial and socio-economic influences. Arch Int Med 150:849-853, 1990
39. BAKIR AA, LEVY PS, DUNEA G: The prognosis of lupus nephritis in African-Americans: A retrospective analysis. Am J Kidney Dis 24:159-171, 1994
40. AUSTIN HA, BOUMPAS DT, VAUGHAN EM, BALOW JE: Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data. Kidney Int 45:544-550, 1994
41. KARLSON EW, DALTROY LH, LEW RA, WRIGHT EA, PARTRIDGE AJ, ROBERTS WN, STERN SH, STRAATON KV, WACHOLTZ MC, GROSFLAM JM, LLIANG MH: The independence and stability of socioeconomic predictors of morbidity in systemic lupus erythematosus. Arthritis Rheum 38:267-273, 1995
42. WARD MM, STUDENSKI S: Age associated clinical manifestations of systemic lupus erythematosus: A multivariate regression analysis. J Rheum 17:476-481, 1990
43. FRIES JF, HOLMAN FR: Systemic Lupus Erythematosus: A Clinical Analysis. Philadelphia, W.B. Saunders Co, 1975
44. WALLACE DJ, HAHN BH: Dubois' Lupus Erythematosus (4th ed), Philadelphia, Lea & Febiger, 1993
45. GIBSON T, MYERS AR: Nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis 35:398-406, 1976
46. WILSON WA, SCOPELITIS E, MICHALSKI JP: Association of HLA-DR7 with both antibody to SSA (Ro) and disease susceptibility in blacks with systemic lupus erythematosus. J Rheumatol 11:653-657, 1984
47. ARNETT FC, HAMILTON RG, ROEBBER MG, HARLEY JB, REICHLIN M: Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus. J Rheumatol 15:1773-1776, 1988
48. HOWARD PF, HOCHBERG MC, BIAS WB, ARNETT FC, MCLEAN RH: Relationship between C4 null alleles, HLA-D region antigens, and genetic susceptibility to systemic lupus erythematosus in caucasian and black Americans. Am J Med 81:187-193, 1986
49. GOLDSTEIN R, OLSEN ML, ARNETT FC, DUVIC M, POLLACK MS, REVEILLE JD: Deletion of C4A genes in black Americans with systemicv lupus erythematosus (abstract). Arthritis Rheum 31 (Suppl): S22, 1988
50. ALARIF LI, RUPPERT GB, WILSON R JR: HLA-DR antigens in blacks with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 10:297, 1983
51. KACHRU RB, SEQUEIRA W, MITTAL KK: A significant increase in HLA-DR3 and DR2 in systemic lupus erythematosus among blacks. J Rheumatol 11:471, 1984
52. SALMON JE, MILLARD S, SCHACHTER LA, ARNETT FC, GINZLER EM, GOURLEY MF, RAMSEY-GOLDMAN R, PETERSON MGE, KIMBERLY RP: FcγRIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1348-1354, 1996
53. JARJOUR W, REED AM, GAUTHIER J, HUNT S, WINFIELD JB: The 8.5-kb PstI allele of the stress protein gene, Hsp 70-2: An independent risk factor for systemic lupus erythematosus in African Americans? Hum Immunol 4:1-5, 1995